Prognostic significance of 14v-lymph node dissection to D2 dissection for lower-third gastric cancer

Table 1 Clinicopathological characteristics of the entire study population, n (%)

Characteristics	Propensity score matched patients (n = 130)			P-value
	14vD (-) (n = 65)	14vD (+) (n = 65)
		LNM (-) (n = 57)	LNM (+) (n = 8)
Age group				0.323
< 65 yr	45 (69.2)	43 (66.2)	7 (10.8)
≥ 65 yr	20 (30.8)	14 (21.5)	1 (1.5)
Gender				0.149
Male	36 (55.4)	37 (56.9)	7 (10.8)
Female	29 (44.6)	20 (30.8)	1 (1.5)
Tumor size
< 4 cm	33 (50.8)	27 (41.5)	3 (4.6)	0.559
≥ 4 cm	32 (49.2)	30 (46.2)	5 (7.7)
Histologic grade				0.537
Differentiated	17 (26.2)	11 (16.9)	3 (4.6)
Undifferentiated	48 (73.8)	46 (70.8)	5 (7.7)
pT stage				0.488
T1	9 (13.9)	6 (9.2)	0
T2	16 (24.6)	17 (26.2)	2 (3.1)
T3	13 (20.0)	19 (29.3)	1 (1.5)
T4a	26 (40.0)	14 (21.5)	5 (7.7)
T4b	1 (1.5)	1 (1.5)	0
pN stage				0.788
N0	27 (41.6)	22 (33.8)	0
N1	8 (12.3)	6 (9.2)	1 (1.5)
N2	14 (21.5)	15 (23.2)	1 (1.5)
N3a	13 (20.0)	14 (21.5)	4 (6.2)
N3b	3 (4.6)	0	2 (3.1)
pTNM stage				0.288
IA	8 (12.3)	3 (4.6)	0
IB	11 (16.9)	7 (10.8)	0
IIA	3 (4.6)	10 (15.4)	0
IIB	12 (18.5)	13 (20.0)	0
IIIA	16 (24.6)	14 (21.5)	3 (4.6)
IIIB	13 (20.0)	10 (15.4)	4 (6.2)
IIIC	2 (3.1)	0	1 (1.5)
postoperative chemotherapy				0.856
Yes	24 (36.9)	22 (33.8)	3 (4.6)
No	41 (63.1)	35 (53.9)	5 (7.7)

P-value is the result of comparison of the 14vD (-) group and the 14vD (+) group. LNM (-): Without 14v lymph nodes metastasis; LNM (+): With 14v lymph nodes metastasis.

Table 2 Univariate and multivariate analyses of prognostic factors for the entire study population

Variable	Univariate analysis		Multivariate analysis
	Hazard ratio (95%CI)	P-value	Hazard ratio (95%CI)	P-value
Status of 14v dissection		0.980		0.900
14vD (-)	1 (ref)		1 (ref)
14vD (+)	1.01 (0.64-1.58)		0.97 (0.59-1.60)
Age group		0.569		0.234
< 65 yr	1 (ref)		1 (ref)
≥ 65 yr	1.15 (0.71-1.86)		1.40 (0.80-2.45)
Gender		0.781
Male	1 (ref)		1 (ref)	0.721
Female	0.94 (0.60-1.46)		0.91 (0.56-1.50)
Tumor size		0.455		0.448
< 4 cm	1 (ref)		1 (ref)
≥ 4 cm	1.19 (0.76-1.86)		0.82 (0.50-1.56)
Histologic grade		0.275		0.162
Differentiated	1 (ref)		1 (ref)
Undifferentiated	1.34 (0.80-2.24)		1.51 (0.85-2.71)
pT stage		0.004		0.033
T1	1 (ref)		1 (ref)
T2	4.88 (1.13-20.99)		4.97 (1.11-22.28)
T3	8.32 (1.96-35.29)		6.58 (1.45-29.92)
T4	9.17 (2.2-38.21)		7.87 (1.84-33.74)
pN stage		0.002		0.018
N0	1 (ref)		1 (ref)
N1	2.29 (1.07-4.90)		2.08 (0.92-4.67)
N2	2.18 (1.20-3.97)		2.01 (1.06-3.81)
N3a	3.11 (1.71-5.63)		2.82 (1.49-5.36)
N3b	4.30 (1.46-12.65)		3.90 (1.22-12.45)
Postoperative chemotherapy		0.799		0.368
No	1 (ref)		1 (ref)
Yes	1.06 (0.67-1.70)		0.78 (0.46-1.33)

Table 3 Univariate and multivariate analyses of prognostic factors for patients with pathological stage IIIA gastric cancer

Variable	Univariate analysis		Multivariate analysis
	Hazard ratio (95%CI)	P-value	Hazard ratio (95%CI)	P-value
Status of 14v dissection		0.027		0.342
14vD (-)	1 (ref)		1 (ref)
14vD (+)	0.39 (0.17-0.90)		0.61 (0.22-1.70)
Age group		0.331		0.018
< 65 yr	1 (ref)		1 (ref)
≥ 65 yr	1.53 (0.65-3.64)		7.23 (1.41-37.06)
Gender		0.986		0.930
Male	1 (ref)		1 (ref)
Female	0.99 (0.44-2.24)		1.05 (0.36-3.09)
Tumor size		0.091		0.091
< 4 cm	1 (ref)		1 (ref)
≥ 4 cm	0.46 (0.19-1.13)		0.37 (0.12-1.17)
Histologic grade		0.220		0.091
Differentiated	1 (ref)		1 (ref)
Undifferentiated	1.71 (0.73-4.02)		2.71 (0.85-8.60)
pT stage		0.154		0.006
T2-3	1 (ref)		1 (ref)
T4	1.35 (0.89-2.04)		14.15 (2.11-95.06)
pN stage		0.886		0.335
N0-1	1 (ref)		1 (ref)
N2	0.86 (0.33-2.25)		1.77 (0.55-5.72)
N3a	0.74 (0.22-2.49)		3.69 (0.64-21.37)
Postoperative chemotherapy		0.936		0.586
No	1 (ref)		1 (ref)
Yes	0.96 (0.39-2.37)		0.75 (0.27-2.11)